DNA repair by homologous recombination, but not by nonhomologous end joining, is elevated in breast cancer cells

Neoplasia

Volumn 11, Issue 7, 2009, Pages 683-691

  Mao, Zhiyong ^a   Jiang, Ying ^a   Liu, Xiang ^a   Seluanov, Andrei ^a   Gorbunova, Vera ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EPITHELIUM CELL; GAMMA IRRADIATION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; NONHOMOLOGOUS END JOINING; PRIORITY JOURNAL; RADIOSENSITIVITY;

EID: 67650477223     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09312     Document Type: Article

References (50)

1. Davidson JM, Gorringe KL, Chin SF, Orsetti B, Besret C, Courtay-Cahen C, Roberts I, Theillet C, Caldas C, and Edwards PA (2000). Molecular cytogenetic analysis of breast cancer cell lines. Br J Cancer 83, 1309-1317.
2. Forozan F, Mahlamaki EH, Monni O, Chen Y, Veldman R, Jiang Y, Gooden GC, Ethier SP, Kallioniemi A, and Kallioniemi OP (2000). Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res 60, 4519-4525.
3. Kytola S, Rummukainen J, Nordgren A, Karhu R, Farnebo F, Isola J, and Larsson C (2000). Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping. Genes Chromosomes Cancer 28, 308-317.
4. Loveday RL, Greenman J, Simcox DL, Speirs V, Drew PJ, Monson JR, and Kerin MJ (2000). Genetic changes in breast cancer detected by comparative genomic hybridisation. Int J Cancer 86, 494-500.
5. Helleday T, Lo J, van Gent DC, and Engelward BP (2007). DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst) 6, 923-935.
6. San Filippo J, Sung P, and Klein H (2008). Mechanism of eukaryotic homologous recombination. Annu Rev Biochem 77, 229-257.
7. Kennedy RD and D'Andrea AD (2005). The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev 19, 2925-2940.
8. Lieber MR (2008). The mechanism of human nonhomologous DNA end joining. J Biol Chem 283, 1-5.
9. King MC, Marks JH, and Mandell JB (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302, 643-646.
10. Boulton SJ (2006). Cellular functions of the BRCA tumour-suppressor proteins. Biochem Soc Trans 34, 633-645.
11. Chaney SG and Sancar A (1996). DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 88, 1346-1360.
12. Weichselbaum RR, Dahlberg W, Beckett M, Karrison T, Miller D, Clark J, and Ervin T (1986). Radiation-resistant and repair-proficient human tumor cells may be associated with radiotherapy failure in head- and neck-cancer patients. Proc Natl Acad Sci USA 83, 2684-2688.
13. Panasci L, Paiement JP, Christodoulopoulos G, Belenkov A, Malapetsa A, and Aloyz R (2001). Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair. Clin Cancer Res 7, 454-461.
14. Maacke H, Jost K, Opitz S, Miska S, Yuan Y, Hasselbach L, Luttges J, Kalthoff H, and Sturzbecher HW (2000). DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 19, 2791-2795.
15. Raderschall E, Stout K, Freier S, Suckow V, Schweiger S, and Haaf T (2002). Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res 62, 219-225.
16. Xia SJ, Shammas MA, and Shmookler Reis RJ (1997). Elevated recombination in immortal human cells is mediated by HsRAD51 recombinase. Mol Cell Biol 17, 7151-7158.
17. Henning Wand Sturzbecher HW (2003). Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. Toxicology 193, 91-109.
18. Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO, Pierce AJ, Fishel R, and Skorski T (2001). BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 8, 795-806.
19. Maacke H, Opitz S, Jost K, Hamdorf W, Henning W, Kruger S, Feller AC, Lopens A, Diedrich K, Schwinger E, et al. (2000). Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer 88, 907-913.
20. Maacke H, Hundertmark C, Miska S, Voss M, Kalthoff H, and Sturzbecher HW (2002). Autoantibodies in sera of pancreatic cancer patients identify recombination factor Rad51 as a tumour-associated antigen. J Cancer Res Clin Oncol 128, 219-222.
21. Christodoulopoulos G, Malapetsa A, Schipper H, Golub E, Radding C, and Panasci LC (1999). Chlorambucil induction of HsRad51 in B-cell chronic lymphocytic leukemia. Clin Cancer Res 5, 2178-2184.
22. Richardson C (2005). RAD51, genomic stability, and tumorigenesis. Cancer Lett 218, 127-139.
23. Hine CM, Seluanov A, and Gorbunova V (2008). Use of the Rad51 promoter for targeted anti-cancer therapy. Proc Natl Acad Sci USA 105, 20810-20815.
24. Seluanov A, Mittelman D, Pereira-Smith OM, Wilson JH, and Gorbunova V (2004). DNA end joining becomes less efficient and more error-prone during cellular senescence. Proc Natl Acad Sci USA 101, 7624-7629.
25. Mao Z, Seluanov A, Jiang Y, and Gorbunova V (2007). TRF2 is required for repair of nontelomeric DNA double-strand breaks by homologous recombination. Proc Natl Acad Sci USA 104, 13068-13073.
26. Richardson C, Stark JM, Ommundsen M, and Jasin M (2004). Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability. Oncogene 23, 546-553.
27. Vispe S, Cazaux C, Lesca C, and Defais M (1998). Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res 26, 2859-2864.
28. Lambert S and Lopez BS (2000). Characterization of mammalian RAD51 double strand break repair using non-lethal dominant-negative forms. EMBO J 19, 3090-3099.
29. Canitrot Y, Capp JP, Puget N, Bieth A, Lopez B, Hoffmann JS, and Cazaux C (2004). DNA polymerase beta overexpression stimulates the Rad51-dependent homologous recombination in mammalian cells. Nucleic Acids Res 32, 5104-5112.
30. Bishop AJ and Schiestl RH (2002). Homologous recombination and its role in carcinogenesis. J Biomed Biotechnol 2, 75-85.
31. Reliene R, Bishop AJ, and Schiestl RH (2007). Involvement of homologous recombination in carcinogenesis. Adv Genet 58, 67-87.
32. Martin RW, Orelli BJ, Yamazoe M, Minn AJ, Takeda S, and Bishop DK (2007). RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors. Cancer Res 67, 9658-9665.
33. Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J, Fishel R, and Skorski T (2002). Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 22, 4189-4201.
34. Takata M, Sasaki MS, Sonoda E, Morrison C, Hashimoto M, Utsumi H, Yamaguchi-Iwai Y, Shinohara A, and Takeda S (1998). Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J 17, 5497-5508.
35. Shrivastav M, De Haro LP, and Nickoloff JA (2008). Regulation of DNA double-strand break repair pathway choice. Cell Res 18, 134-147.
36. Mao Z, Bozzella M, Seluanov A, and Gorbunova V (2008). DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells. Cell Cycle 7, 2902-2906.
37. Kauffmann A, Rosselli F, Lazar V, Winnepenninckx V, Mansuet-Lupo A, Dessen P, van den Oord JJ, Spatz A, and Sarasin A (2008). High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 27, 565-573.
38. Sarasin A and Kauffmann A (2008). Overexpression of DNA repair genes is associated with metastasis: a new hypothesis. Mutat Res 659, 49-55.
39. Merel P, Prieur A, Pfeiffer P, and Delattre O (2002). Absence of major defects in non-homologous DNA end joining in human breast cancer cell lines. Oncogene 21, 5654-5659.
40. Windhofer F, Krause S, Hader C, Schulz WA, and Florl AR (2008). Distinctive differences in DNA double-strand break repair between normal urothelial and urothelial carcinoma cells. Mutat Res 638, 56-65.
41. Deriano L, Guipaud O, Merle-Beral H, Binet JL, Ricoul M, Potocki-Veronese G, Favaudon V, Maciorowski Z, Muller C, Salles B, et al. (2005). Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the non-homologous end-joining DNA repair pathway. Blood 105, 4776-4783.
42. Kim CH, Park SJ, and Lee SH (2002). A targeted inhibition of DNA-dependent protein kinase sensitizes breast cancer cells following ionizing radiation. J Pharmacol Exp Ther 303, 753-759.
43. Sak A, Stuschke M, Wurm R, Schroeder G, Sinn B, Wolf G, and Budach V (2002). Selective inactivation of DNA-dependent protein kinase with antisense oligodeoxynucleotides: consequences for the rejoining of radiation-induced DNA double-strand breaks and radiosensitivity of human cancer cell lines. Cancer Res 62, 6621-6624.
44. Belenkov AI, Paiement JP, Panasci LC, Monia BP, and Chow TY (2002). An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents. Cancer Res 62, 5888-5896.
45. Li GC, He F, Shao X, Urano M, Shen L, Kim D, Borrelli M, Leibel SA, Gutin PH, and Ling CC (2003). Adenovirus-mediated heat-activated antisense Ku70 expression radiosensitizes tumor cells in vitro and in vivo. Cancer Res 63, 3268-3274.
46. Ohnishi T, Taki T, Hiraga S, Arita N, and Morita T (1998). In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochem Biophys Res Commun 245, 319-324.
47. Collis SJ, Tighe A, Scott SD, Roberts SA, Hendry JH, and Margison GP (2001). Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucl Acids Res 29, 1534-1538.
48. Russell JS, Brady K, Burgan WE, Cerra MA, Oswald KA, Camphausen K, and Tofilon PJ (2003). Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res 63, 7377-7383.
49. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, and Helleday T (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917.
50. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921.